Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base

NCT ID: NCT02951546

Last Updated: 2022-05-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2022-02-28

Brief Summary

Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the "metabolic flexibility" need to be better clarified.

It is known that a dietary intervention, accompanied by a physical personalized training, reduce either the hepatic fat content either insulin resistance.

Therefore, the aim of the study is to evaluate "metabolic flexibility" in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated.

Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how "healthy diets" could operate in the clinical treatment of NAFLD and related conditions.

Detailed Description

Nonalcoholic fatty liver disease (NAFLD) is frequently associated to obesity and metabolic syndrome. In NAFLD, a heritable component to disease susceptibility has been demonstrated: the variants of the genes PNPLA3 and TM6SF2 are the most involved genetic determinants.

To date, biochemical mechanisms that affect the "metabolic flexibility" in obese NAFLD subjects, in presence or absence of genetic susceptibility, need to be better clarified.

Different studies demonstrated that a dietary intervention, accompanied by a physical personalized training, significantly reduce either the hepatic fat content either insulin resistance in overweight and obese subjects, independently of weight loss.

On these bases, the aim of the study is to evaluate "metabolic flexibility" in obese NAFLD subjects taking in account their genetics (presence or absence of PNPLA3 and TM6SF2 polymorphisms) and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). In addition, the composition of gut microbiota will be evaluated.

Finally, in this study, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested in order to comprehend whether and how "healthy diets" could be effective not only in the prevention, but also in the clinical treatment of NAFLD and other related conditions.

Conditions

Non-alcoholic Fatty Liver Disease; Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Mediterranean diet

Hypocaloric Mediterranean diet for a 4-month period;

Aerobic exercise training for a 4-month period;

Group Type: EXPERIMENTAL

Mediterranean diet

Intervention Type: DIETARY_SUPPLEMENT

In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.

Aerobic exercise

Intervention Type: OTHER

A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the "FITT" principles (frequency, intensity, time and type).

Low fat diet

Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;

Aerobic exercise training for a 4- month period;

Group Type: EXPERIMENTAL

Low fat diet

Intervention Type: DIETARY_SUPPLEMENT

In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.

Aerobic exercise

Intervention Type: OTHER

A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the "FITT" principles (frequency, intensity, time and type).

Interventions

Mediterranean diet

In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.

Intervention Type: DIETARY_SUPPLEMENT

Low fat diet

In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.

Intervention Type: DIETARY_SUPPLEMENT

Aerobic exercise

A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the "FITT" principles (frequency, intensity, time and type).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• body mass index (BMI) > 30 Kg/m2 and < 40 Kg/m2;
• Caucasian Italian subjects
• hepatic steatosis according with ultrasonographic Hamaguchi's criteria and/or hypertransaminasemia (ALT >30 IU/L in men and >20 IU/L in women)

Exclusion Criteria

• any malignant disease during the last 5 years;
• any inflammatory or autoimmune disease;
• corticosteroids for systemic use;
• renal failure (GFR<90 ml/min);
• heart failure (NYHA classes II-IV);
• history of viral or autoimmune liver disease;
• any cause cirrhosis;
• excessive alcohol intake (>140g/week for men and 70g/week for women);
• participation in a reducing-weight program in the last 3 months;
• level of physical activity higher than 3 METs;
• therapy with antibiotics during the last 3 months;
• bile salts, cholestyramine during the last 6 months before enrollment;
• previous cholecystectomy;
• gallbladder disease

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bambino Gesù Hospital and Research Institute

OTHER

Sponsor Role: collaborator

Università degli studi di Roma Foro Italico

OTHER

Sponsor Role: collaborator

Göteborg University

OTHER

Sponsor Role: collaborator

University of Roma La Sapienza

OTHER

Sponsor Role: lead

Responsible Party

STEFANO GINANNI CORRADINI

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stefano Ginanni Corradini, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department Translational and Precision Medicine, Sapienza University of Rome

Locations

Department of Translational and Precision Medicine, Sapienza University of Rome, Umberto I Hospital

Rome, , Italy

Countries

Italy

Other Identifiers

RIF.CE:4119

Identifier Type: -

Identifier Source: org_study_id